The growing popularity of weight-loss medications such as Ozempic and Wegovy has brought attention to an unexpected issue being called “Ozempic Feet.” While these medications have transformed the treatment of type 2 diabetes and obesity, some people experiencing substantial weight loss are noticing changes in the appearance, comfort and structure of their feet. The term Ozempic Feet is not an officially recognised medical diagnosis, but rather a popular description of foot-related changes that may accompany rapid or significant weight reduction. As more people use GLP-1 medications, podiatrists and other healthcare professionals are taking a closer look at how changes in body weight and fat distribution may affect foot health.

What Causes Ozempic Feet?

One of the main concerns associated with Ozempic Feet is the potential reduction of fatty cushioning beneath the soles of the feet. The heel and ball of the foot contain specialised fat pads that help absorb shock, distribute pressure and protect underlying bones and joints during walking and standing. Significant weight loss can change the amount and distribution of soft tissue throughout the body, potentially affecting these protective structures. However, there is currently limited scientific evidence demonstrating that Ozempic directly causes plantar fat pad atrophy. Ageing, genetics, repetitive loading and certain medical conditions are already recognised contributors to thinning of the foot’s natural cushioning.

The Latest Developments in 2026

During 2026, Ozempic Feet has attracted increasing media attention, particularly as podiatrists report seeing patients whose feet have changed following substantial weight loss. In November, specialists interviewed by Yahoo Health described patients experiencing heel pain, reduced cushioning and changes in footwear fit. Dr Rock Positano, from New York’s Hospital for Special Surgery, explained that the amount and speed of weight loss appear to be important factors. Similar complaints have been observed following bariatric surgery, suggesting the changes are not unique to GLP-1 medications.

Symptoms and Footwear Changes

People describing Ozempic Feet commonly report more prominent veins and tendons, wrinkled skin, narrower feet and shoes that suddenly feel too large. Others experience tenderness beneath the heel or forefoot, particularly when walking barefoot on hard surfaces. Some patients describe discomfort resembling walking on small stones. Reduced foot volume may also create footwear problems, including heel slippage, friction and instability. Importantly, not every person losing weight experiences these symptoms, and foot pain should not automatically be attributed to medication-related weight loss.

Can Ozempic Actually Improve Foot Health?

Interestingly, weight loss may also provide substantial benefits for foot health. Reducing excess body weight decreases mechanical loading on the feet, potentially relieving symptoms associated with plantar heel pain and other weight-related musculoskeletal conditions. Emerging research also suggests GLP-1 medications may have beneficial effects on certain diabetes-related foot complications. A November 2026 clinical review highlighted observational evidence linking these medications with lower rates of diabetic foot ulcers and amputations, although further research is needed to establish whether the medications themselves provide these protective effects.

Treatment and Prevention

For people experiencing discomfort, podiatrists generally recommend reassessing footwear, using supportive shoes with adequate cushioning, and considering heel cups or shock-absorbing insoles. Avoiding prolonged barefoot walking on hard surfaces may also help. Maintaining adequate protein intake and incorporating resistance exercise during weight loss can support muscle preservation. Persistent heel or forefoot pain warrants professional assessment, particularly in people with diabetes, where neuropathy and circulation problems must also be considered.

What Happens Next?

The biggest unanswered question is whether GLP-1-associated weight loss produces measurable, lasting changes in the specialised fat pads beneath the feet. Currently, direct clinical evidence remains limited, and dedicated studies are needed to establish how frequently these changes occur and whether they are reversible.

For now, Ozempic Feet is best understood as a possible consequence of substantial weight loss rather than a proven direct drug side effect. With appropriate footwear, foot care and professional advice, many associated symptoms may be manageable without sacrificing the broader health benefits of medically supervised weight reduction.